Drug-class-specific changes in the volume and cost of antidiabetic medications in Poland between 2012 and 2015.

Andrzej ŚliwczyńskiMelania BrzozowskaAndrzej JacynaPetre IltchevTymoteusz IwańczukWaldemar WierzbaMichał MarczakKatarzyna OrlewskaPiotr SzymańskiEwa Orlewska

Published in: PloS one (2017)

The observed tendencies correspond to the evidence-based HTA recommendations. The reimbursement status, the ratio of cost to clinical outcomes and data on the long-term safety have a deciding impact on how a drug is used.

Keyphrases

adverse drug
electronic health record
big data
drug induced
clinical practice
emergency department
data analysis